Matthew Taylor analyst UBS

Currently out of the existing stock ratings of Matthew Taylor, 125 are a BUY (59.52%), 68 are a HOLD (32.38%), 17 are a SELL (8.1%).

Matthew Taylor

Work Performance Price Targets & Ratings Chart

Analyst Matthew Taylor, employed at UBS, carries an average stock price target met ratio of 68.79% that have a potential upside of 17.89% achieved within 158 days on average. Previously, Matthew Taylor worked at JEFFERIES.

Matthew Taylor’s has documented 382 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MDT, Medtronic PLC at 24-May-2024.

Wall Street Analyst Matthew Taylor

Analyst best performing recommendations are on INMD (INMODE LTD).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE) at 11/27/2018. The price target of $36 was fulfilled within 2 days with a profit of $2.71 (8.14%) receiving and performance score of 40.7.

Average potential price target upside

ABT Abbott Laboratories BAX Baxter International BDX Becton Dickinson and Company DXCM DexCom EW Edwards Lifesciences Corp GMED Globus Medical INMD InMode Ltd ISRG Intuitive Surgical MASI Masimo MDT Medtronic PLC NUVA NuVasive PHG Koninklijke Philips NV ADR TFX Teleflex orporated UTRS Minerva Surgical VAR Varian Medical Systems LIVN LivaNova PLC PODD Insulet RMD ResMed IART Integra LifeSciences Holdings NVRO Nevro Corp TNDM Tandem Diabetes Care ZBH Zimmer Biomet Holdings SYK Stryker ATEC Alphatec Holdings BSX Boston Scientific Corp AXNX Axonics Modulation Technologies PEN Penumbra CNMD CONMED HRC Hill-Rom Holdings ESTA Establishment Labs Holdings SENS Senseonics Holdings SIBN Si-Bone VREX Varex Imaging Corp

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

140

$36.01 (34.63%)

141

1 months 28 days ago

13/22 (59.09%)

$32.93 (30.76%)

291

Buy

125

$21.01 (20.20%)

114

2 months 15 days ago

4/5 (80%)

$14.89 (13.52%)

388

Buy

126

$22.01 (21.17%)

130

4 months 25 days ago

7/14 (50%)

$13.55 (12.05%)

292

Buy

127

$23.01 (22.13%)

110

4 months 25 days ago

12/18 (66.67%)

$14.55 (12.94%)

190

Buy

125

$21.01 (20.20%)

125

4 months 26 days ago

6/7 (85.71%)

$14.23 (12.85%)

250

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Matthew Taylor is most bullish on?

Potential upside of $63.6 has been obtained for PODD (INSULET)

Which stock is Matthew Taylor is most reserved on?

Potential downside of -$48.27 has been obtained for RMD (RESMED)

What Year was the first public recommendation made by Matthew Taylor?

On 2010

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?